不同临床表型代谢相关脂肪性肝病的发病机制及中西医结合治疗策略

赵文霞; 高磊; 陈欣菊; 郑瑗瑗; 刘素彤; 张丽慧; 赵晴; 赵晨露

doi:10.12449/JCH260423

不同临床表型代谢相关脂肪性肝病的发病机制及中西医结合治疗策略

DOI: 10.12449/JCH260423

赵文霞^{1, 2, 3, , ,},
高磊^4, , ,,
陈欣菊¹,
郑瑗瑗¹,
刘素彤^{1, 2, 3},
张丽慧^{1, 2, 3},
赵晴^{1, 2, 3},
赵晨露^{1, 2, 3}

1.
河南中医药大学第一附属医院脾胃肝胆科，郑州 450000
2.
河南省中医科学院全国名中医赵文霞研究所，郑州 450000
3.
中西医防治重大疾病河南省协同创新中心，郑州 450000
4.
广州中医药大学基础医学院，广州 510006

基金项目:

国家自然科学基金项目 (82205086);

全国名中医传承工作室建设项目 (National Medical Affairs Office, Renjiaohan ［2022］ No.245);

国家科技重大专项自主项目 (2018ZX1030502)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：赵文霞负责拟定写作思路并撰写论文；高磊、陈欣菊负责设计论文框架；郑瑗瑗负责整理资料；刘素彤、张丽慧、赵晴、赵晨露负责文献检索与整理。

详细信息

通信作者:
赵文霞， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）

高磊， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

计量
- 文章访问数: 11
- HTML全文浏览量: 2
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2025-12-31
- 录用日期: 2026-01-19
- 出版日期: 2026-04-25

Metabolic dysfunction-associated fatty liver disease with different clinical phenotypes： Pathogenesis and strategies for integrated traditional Chinese and Western medicine treatment

Wenxia ZHAO^{1, 2, 3
, ,
,},
Lei GAO^{4
, ,
,},
Xinju CHEN¹,
Yuanyuan ZHENG¹,
Sutong LIU^{1, 2, 3},
Lihui ZHANG^{1, 2, 3},
Qing ZHAO^{1, 2, 3},
Chenlu ZHAO^{1, 2, 3}

1.
Spleen，Stomach and Hepatobiliary Department，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
2.
Research Institute of National Famous Traditional Chinese Medicine Expert Zhao Wenxia，Henan Academy of Chinese Medicine Sciences，Zhengzhou 450000，China
3.
Henan Province Collaborative Innovation Center for Prevention and Treatment of Major Diseases by Chinese and Western Medicine，Zhengzhou 450000，China
4.
School of Basic Medical Sciences，Guangzhou University of Chinese Medicine，Guangzhou 510006，China

Research funding:

National Natural Science Foundation of China (82205086);

National Famous Traditional Chinese Medicine Inheritance Studio Construction Project (National Medical Affairs Office, Renjiaohan ［2022］ No.245);

Independent Project of National Science and Technology Major Project (2018ZX1030502)

More Information

Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）; GAO Lei， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

摘要

摘要: 代谢相关脂肪性肝病（MAFLD）是一种病因复杂的慢性代谢性肝病。不同临床表型如肥胖、高脂血症、2型糖尿病、绝经后以及慢性乙型肝炎在MAFLD发生发展中的作用机制各异，导致该病在临床进程及预后方面存在高度异质性。本文旨在系统总结肥胖、高脂血症、2型糖尿病、绝经后、慢性乙型肝炎等5种不同临床表型MAFLD的发病机制及临床特征，并据此阐述相应的个体化中西医诊疗方案，以期为临床实践提供参考并提高临床诊疗水平。
- 代谢相关脂肪性肝病 /
- 肥胖症 /
- 高脂血症 /
- 糖尿病， 2型 /
- 绝经后期 /
- 乙型肝炎，慢性
Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD） is a chronic metabolic liver disorder with complex etiologies. Different clinical phenotypes of MAFLD （such as obesity， hyperlipidemia， type 2 diabetes mellitus， the postmenopausal state， and chronic hepatitis B） have different mechanisms of action in the development and progression of MAFLD， leading to high heterogeneity in its clinical progression and prognosis. This article systematically reviews the pathogeneses and clinical features of the above five clinical phenotypes of MAFLD and elaborates on the corresponding individualized diagnosis and treatment regimens integrating traditional Chinese medicine and Western medicine， in order to provide a reference for clinical practice and improve clinical diagnosis and treatment.
- Metabolic Dysfunction-Associated Fatty Liver Disease /
- Obesity /
- Hyperlipidemias /
- Diabetes Mellitus， Type 2 /
- Postmenopause /
- Hepatitis B， Chronic

HTML全文

注： IR，胰岛素抵抗。

图 1 代谢相关脂肪性肝病不同临床表型的发病机制及中西医结合治疗

Figure 1. Pathogenesis and integrated traditional Chinese and western medicine treatment of different clinical phenotypes of MAFLD

下载: 全尺寸图片幻灯片

参考文献(56)

[1]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[2]	DEY P. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: What's different?[J]. Front Endocrinol, 2025, 16: 1693123. DOI: 10.3389/fendo.2025.1693123.
[3]	ZENG Q, LI NS, PAN XF, et al. Clinical management and treatment of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9( 6): 393- 405. DOI: 10.1016/S2213-8587(21)00047-4.
[4]	THEOFILIS P, VORDONI A, NAKAS N, et al. Endothelial dysfunction in nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Life, 2022, 12( 5): 718. DOI: 10.3390/life12050718.
[5]	GAO D, BING C, GRIFFITHS HR. Disrupted adipokine secretion and inflammatory responses in human adipocyte hypertrophy[J]. Adipocyte, 2025, 14( 1): 2485927. DOI: 10.1080/21623945.2025.2485927.
[6]	JIN X, QIU TT, LI L, et al. Pathophysiology of obesity and its associated diseases[J]. Acta Pharm Sin B, 2023, 13( 6): 2403- 2424. DOI: 10.1016/j.apsb.2023.01.012.
[7]	SATO S, IINO C, SASADA T, et al. A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population[J]. Environ Health Prev Med, 2025, 30: 17. DOI: 10.1265/ehpm.24-00365.
[8]	GENG YN, FABER KN, de MEIJER VE, et al. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?[J]. Hepatol Int, 2021, 15( 1): 21- 35. DOI: 10.1007/s12072-020-10121-2.
[9]	CHENG ST, YANG D, LI QJ, et al. Ameliorative effect of puerarin on non-alcoholic fatty liver disease induced by high-fat diet in mice and its mechanism[J]. J Jilin Univ(Med Ed), 2026, 52( 1): 44- 55. DOI: 10.13481/j.1671-587X.20260106. 陈思童, 杨丹, 李庆杰, 等. 葛根素对高脂饮食诱导小鼠非酒精性脂肪性肝病的改善作用及其机制[J]. 吉林大学学报(医学版), 2026, 52( 1): 44- 55. DOI: 10.13481/j.1671-587X.20260106.
[10]	GAO G, ZHAO J, DING J, et al. Alisol B regulates AMPK/mTOR/SREBPs via directly targeting VDAC1 to alleviate hyperlipidemia[J]. Phytomedicine, 2024, 128: 155313. DOI: 10.1016/j.phymed.2023.155313.
[11]	SHENG W, JI G, ZHANG L. Role of macrophage scavenger receptor MSR1 in the progression of non-alcoholic steatohepatitis[J]. Front Immunol, 2022, 13: 1050984. DOI: 10.3389/fimmu.2022.1050984.
[12]	MOHIUDDIN MS, NEHA NT, MAHIR JUK, et al. Metabolic dysfunction associated fatty liver disease and type 2 diabetes: Pathophysiological links, epidemiological trends, and clinical implications[J]. Front Endocrinol, 2025, 16: 1669478. DOI: 10.3389/fendo.2025.1669478.
[13]	TANASE DM, GOSAV EM, COSTEA CF, et al. The intricate relationship between type 2 diabetes mellitus(T2DM), insulin resistance(IR), and nonalcoholic fatty liver disease(NAFLD)[J]. J Diabetes Res, 2020, 2020: 3920196. DOI: 10.1155/2020/3920196.
[14]	European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD): Executive summary[J]. Diabetologia, 2024, 67( 11): 2375- 2392. DOI: 10.1007/s00125-024-06196-3.
[15]	WU YK, XIE J, TAO Q, et al. Benzopyrene aggravates nonalcoholic liver fatty diseases in female mice via the AHR/ERα axis[J]. Curr Mol Med, 2025, 25( 9): 1191- 1201. DOI: 10.2174/0115665240338923241219152329.
[16]	ZUO QY, PARK NH, LEE JK, et al. Navigating nonalcoholic fatty liver disease(NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style[J]. Steroids, 2024, 203: 109330. DOI: 10.1016/j.steroids.2023.109330.
[17]	DONG JW, DENNIS KMJH, VENKATAKRISHNAN R, et al. The impact of estrogen deficiency on liver metabolism: Implications for hormone replacement therapy[J]. Endocr Rev, 2025, 46( 6): 790- 809. DOI: 10.1210/endrev/bnaf018.
[18]	LU Y, YANG XY, KUANG Q, et al. HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation[J]. Exp Cell Res, 2023, 430( 1): 113721. DOI: 10.1016/j.yexcr.2023.113721.
[19]	TONG X, WAN YW, YIN SX, et al. Comprehensive analysis of chronic hepatitis B concurrent with non-alcoholic fatty liver disease: A proteomics report based on clinical liver samples[J]. Clin Proteomics, 2025, 22( 1): 19. DOI: 10.1186/s12014-024-09523-3.
[20]	JIANG DX, WU XY, CHEN C, et al. Follicular cytotoxic T cells is dysfunctional in chronic hepatitis B patients with non-alcoholic fatty liver disease[J]. Biochim Biophys Acta Mol Basis Dis, 2025, 1871( 3): 167646. DOI: 10.1016/j.bbadis.2024.167646.
[21]	LI JZ, YE LH, WANG DH, et al. The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD[J]. Virus Res, 2021, 298: 198405. DOI: 10.1016/j.virusres.2021.198405.
[22]	SUN HX, FANG D, WANG HD, et al. The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity[J]. Hepatol Int, 2023, 17( 1): 215- 224. DOI: 10.1007/s12072-022-10409-5.
[23]	CIARDULLO S, GRASSI G, MANCIA G, et al. Nonalcoholic fatty liver disease and risk of incident hypertension: A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2022, 34( 4): 365- 371. DOI: 10.1097/MEG.0000000000002299.
[24]	KASPER P, MARTIN A, LANG S, et al. NAFLD and cardiovascular diseases: A clinical review[J]. Clin Res Cardiol, 2021, 110( 7): 921- 937. DOI: 10.1007/s00392-020-01709-7.
[25]	SHENG W, JI G, ZHANG L. Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome[J]. World J Gastroenterol, 2022, 28( 43): 6099- 6108. DOI: 10.3748/wjg.v28.i43.6099.
[26]	MONTEMEZZO M, ALTURKI A, STAHLSCHMIDT F, et al. Nonalcoholic fatty liver disease and coronary artery disease: Big brothers in patients with acute coronary syndrome[J]. Sci World J, 2020, 2020: 8489238. DOI: 10.1155/2020/8489238.
[27]	CHIRIAC S, STANCIU C, GIRLEANU I, et al. Nonalcoholic fatty liver disease and cardiovascular diseases: The heart of the matter[J]. Can J Gastroenterol Hepatol, 2021, 2021: 6696857. DOI: 10.1155/2021/6696857.
[28]	TOH JZK, PAN XH, TAY PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2022, 20( 11): 2462- 2473.e10. DOI: 10.1016/j.cgh.2021.09.021.
[29]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[30]	FERGUSON D, FINCK BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2021, 17( 8): 484- 495. DOI: 10.1038/s41574-021-00507-z.
[31]	SUN WX, LIU DC, YANG T, et al. Increased risk of vascular complications in patients with type 2 diabetes and fatty liver disease[J]. BMC Endocr Disord, 2024, 24( 1): 235. DOI: 10.1186/s12902-024-01766-3.
[32]	POLYZOS SA, GOULIS DG. Menopause and metabolic dysfunction-associated steatotic liver disease[J]. Maturitas, 2024, 186: 108024. DOI: 10.1016/j.maturitas.2024.108024.
[33]	GIANOS E, KARALIS DG, GABALLA D, et al. Managing cardiometabolic risk factors across a woman's lifespan: A lipidologist's perspective[J]. J Clin Lipidol, 2021, 15( 3): 423- 430. DOI: 10.1016/j.jacl.2021.03.005.
[34]	FOUAD Y, ALBORAIE M, SHIHA G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2024, 18( Suppl 2): 827- 833. DOI: 10.1007/s12072-024-10704-3.
[35]	ZHANG SY, ZHANG XX, JIN HM, et al. Adverse effect of nonalcoholic fatty liver disease on the therapeutic response in patients with chronic hepatitis B[J]. J Clin Transl Hepatol, 2023, 11( 1): 67- 75. DOI: 10.14218/JCTH.2022.00066.
[36]	van KLEEF LA, CHOI HSJ, BROUWER WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3( 5): 100350. DOI: 10.1016/j.jhepr.2021.100350.
[37]	HUANG SC, SU TH, TSENG TC, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion[J]. Clin Gastroenterol Hepatol, 2024, 22( 3): 581- 590. e 6. DOI: 10.1016/j.cgh.2023.09.040.
[38]	LINDQVIST C, HOLMER M, HAGSTRÖM H, et al. Macronutrient composition and its effect on body composition changes during weight loss therapy in patients with non-alcoholic fatty liver disease: Secondary analysis of a randomized controlled trial[J]. Nutrition, 2023, 110: 111982. DOI: 10.1016/j.nut.2023.111982.
[39]	NI WJ, GENG N, BAI X, et al. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. J Clin Hepatol, 2024, 40( 8): 1567- 1574. DOI: 10.12449/JCH240810. 倪文婧, 耿楠, 白雪, 等.《2024年欧洲肝病学会/欧洲糖尿病学会/欧洲肥胖症学会临床实践指南: 代谢相关脂肪性肝病的管理》摘译[J]. 临床肝胆病杂志, 2024, 40( 8): 1567- 1574. DOI: 10.12449/JCH240810.
[40]	YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
[41]	ESMAIL VAW, MOHAMMED MO, AL-NIMER MSM. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome[J]. Arab J Gastroenterol, 2021, 22( 1): 1- 5. DOI: 10.1016/j.ajg.2020.12.005.
[42]	WANG SY, SHANG DF, ZHAO CL, et al. Clinical observation on the treatment of hyperlipidemia nonalcoholic steatohepatitis by Jianpi Huatan Qushi prescription combined with Hufu Tongbian scrapp-ing therapy[J]. Chin J Integr Tradit West Med Liver Dis, 2025, 35( 5): 543- 547. DOI: 10.3969/j.issn.1005-0264.2025.005.003. 王思颖, 尚东方, 赵晨露, 等. 健脾化痰祛湿方联合虎符铜砭刮痧法治疗高脂血症性非酒精性脂肪性肝炎的临床观察[J]. 中西医结合肝病杂志, 2025, 35( 5): 543- 547. DOI: 10.3969/j.issn.1005-0264.2025.005.003.
[43]	LIN YH, CAI H, HUANG WQ, et al. Clinical observation of“Linghe decoction” in the treatment of obese non-alcoholic fatty liver disease(syndrome of turbidity-internal obstruction of phlegm)[J]. Tradit Chin Med J, 2024, 23( 1): 50- 53. DOI: 10.14046/j.cnki.zyytb2002.2024.01.013. 林玥宏, 蔡虹, 黄文琪, 等." 苓荷方"治疗肥胖型非酒精性脂肪性肝病(痰浊内阻证)临床观察[J]. 中医药通报, 2024, 23( 1): 50- 53. DOI: 10.14046/j.cnki.zyytb2002.2024.01.013.
[44]	HASHMI K AL, GIGLIO RV, PANTEA STOIAN A, et al. Metabolic dysfunction-associated fatty liver disease: Current therapeutic strategies[J]. Front Nutr, 2024, 11: 1355732. DOI: 10.3389/fnut.2024.1355732.
[45]	LUNA-CASTILLO KP, OLIVARES-OCHOA XC, HERNÁNDEZ-RUIZ RG, et al. The effect of dietary interventions on hypertriglyceridemia: From public health to molecular nutrition evidence[J]. Nutrients, 2022, 14( 5): 1104. DOI: 10.3390/nu14051104.
[46]	ZHAO TT, ZHAO WX, ZHANG LH, et al. Clinical observation on the therapeutic effect of acupoint catgut embedding combined with Dizhuo Huayu Formula on obese non-alcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2024, 34( 6): 517- 520. DOI: 10.3969/j.issn.1005-0264.2024.006.009. 赵婷婷, 赵文霞, 张丽慧, 等. 穴位埋线联合涤浊化瘀方治疗肥胖型非酒精性脂肪性肝病的疗效观察[J]. 中西医结合肝病杂志, 2024, 34( 6): 517- 520. DOI: 10.3969/j.issn.1005-0264.2024.006.009.
[47]	WOOD M, KENNEDY AG, KHAN S, et al. Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: A retrospective cohort study[J]. J Pharm Pract, 2024, 37( 6): 1297- 1302. DOI: 10.1177/08971900241253661.
[48]	CHEN N, GENG N, LI J. Mechanisms and clinical practice advances in weight reduction for patients with metabolic associated fatty liver disease[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 3): 10- 16. DOI: 10.3969/j.issn.1674-7380.2025.03.002. 陈楠, 耿楠, 李婕. 代谢相关脂肪性肝病患者减重治疗机制与临床实践进展[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 3): 10- 16. DOI: 10.3969/j.issn.1674-7380.2025.03.002.
[49]	POKHAREL A, KC S, THAPA P, et al. The effect of empagliflozin on liver fat in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease[J]. Cureus, 2021, 13( 7): e16687. DOI: 10.7759/cureus.16687.
[50]	LI Y, LIU F, ZHANG JW, et al. Observation on the therapeutic effect of Bushen Jianpi formula in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease[J]. J Guangzhou Univ Tradit Chin Med, 2025, 42( 11): 2705- 2713. DOI: 10.13359/j.cnki.gzxbtcm.2025.11.012. 李燕, 刘峰, 张杰文, 等. 补肾健脾方治疗2型糖尿病合并非酒精性脂肪肝病的疗效观察[J]. 广州中医药大学学报, 2025, 42( 11): 2705- 2713. DOI: 10.13359/j.cnki.gzxbtcm.2025.11.012.
[51]	KIM SE, MIN JS, LEE S, et al. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration[J]. Sci Rep, 2023, 13( 1): 15461. DOI: 10.1038/s41598-023-42788-6.
[52]	SONG Y, NI WJ, ZHENG MH, et al. Vitamin E(300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study[J]. Cell Rep Med, 2025, 6( 2): 101939. DOI: 10.1016/j.xcrm.2025.101939.
[53]	ZHAO CL, MA SP, LIU XY, et al. Effects of Danhe Liuwei Dihuang decoction on lipid metabolism and psychological status in postmenopausal patients with NAFLD[J]. Chin J Integr Tradit West Med Liver Dis, 2024, 34( 2): 104- 109. DOI: 10.3969/j.issn.1005-0264.2024.002.002. 赵晨露, 马素平, 刘晓彦, 等. 丹荷六味地黄汤对绝经后NAFLD患者脂代谢及心理状态评分的影响[J]. 中西医结合肝病杂志, 2024, 34( 2): 104- 109. DOI: 10.3969/j.issn.1005-0264.2024.002.002.
[54]	HU DQ, WANG P, WANG XJ, et al. The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis[J]. Heliyon, 2024, 10( 7): e28653. DOI: 10.1016/j.heliyon.2024.e28653.
[55]	GU XH, YANG WG, HU Y, et al. Effects of non-alcoholic fatty liver disease on baseline histology and 96-week entecavir response in treatment-Naïve chronic hepatitis B[J]. Infect Drug Resist, 2025, 18: 6817- 6824. DOI: 10.2147/IDR.S563330.
[56]	ZHAO Q. Clinical efficacy of xiaozhihugan capsules combined with entecavir in treating CHB patients with NAFLD[D]. Zhengzhou: Henan University of Chinese Medicine, 2018. 赵晴. 消脂护肝胶囊联合恩替卡韦治疗慢乙肝合并脂肪肝临床观察[D]. 郑州: 河南中医药大学, 2018.

施引文献

资源附件(0)

访问统计

本文二维码

图(1)

计量

文章访问数: 11
HTML全文浏览量: 2
PDF下载量: 3
被引次数: 0

用微信扫码二维码

分享至好友和朋友圈

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

不同临床表型代谢相关脂肪性肝病的发病机制及中西医结合治疗策略

DOI: 10.12449/JCH260423

通信作者:
赵文霞， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）

高磊， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

计量

Metabolic dysfunction-associated fatty liver disease with different clinical phenotypes： Pathogenesis and strategies for integrated traditional Chinese and Western medicine treatment

Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）; GAO Lei， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

计量

目录

留言板

不同临床表型代谢相关脂肪性肝病的发病机制及中西医结合治疗策略

DOI: 10.12449/JCH260423

通信作者: 赵文霞， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504） 高磊， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

计量

出版历程

Metabolic dysfunction-associated fatty liver disease with different clinical phenotypes： Pathogenesis and strategies for integrated traditional Chinese and Western medicine treatment

Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）; GAO Lei， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）

计量

出版历程

目录

关于本刊

投稿指南

在线期刊

肝胆学院

指南共识

通信作者:
赵文霞， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）

高磊， raygaolei@smu.edu.cn （ORCID： 0000-0001-9030-390X）